What Happened to Marijuana Stocks in 2016?

It's been an eventful year for marijuana stocks, with activity led by GW Pharmaceuticals '(NASDAQ: GWPH) and Corbus Pharmaceuticals '(NASDAQ: CRBP) clinical trial data releases and Insys Therapeutics '(NASDAQ: INSY) approval of its first cannabinoid product, Syndros.

Let's take a look back and see what the future holds for marijuana stocks.

Last resort epilepsy

There's plenty of empirical evidence from medical marijuana and homemade extracts that cannabidiol (CBD), a compound found in marijuana, can help patients with epilepsy. But GW Pharmaceuticals took the more scientifically rigorous route of running placebo-controlled clinical trials in the hopes of gaining Food and Drug Administration approval for its CBD drug, Epidiolex.

Given the stigma associated with a marijuana-derived drug, GW Pharmaceuticals took the smart route, investigating the use of Epidiolex in children with epilepsy who aren't helped by other drugs. When there aren't any other choices, the stigma isn't really an issue.

This year, GW...

e-mail icon Facebook icon Twitter icon LinkedIn icon Reddit icon
Rate this article: 
Region: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.